Last reviewed · How we verify
Placebo as SC Injection
Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.
At a glance
| Generic name | Placebo as SC Injection |
|---|---|
| Sponsor | Carmot Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is administered as a subcutaneous injection in phase 3 trials to serve as a comparator arm, allowing researchers to distinguish the true therapeutic effect of an investigational drug from placebo response and natural disease progression. Any observed clinical benefit in the placebo group is attributed to the placebo effect, regression to the mean, or natural history of the condition.
Approved indications
Common side effects
Key clinical trials
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (PHASE2, PHASE3)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS (PHASE3)
- A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) (PHASE3)
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) (PHASE3)
- Exenatide for Smoking Cessation and Prevention of Weight Gain (PHASE2)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) (PHASE2)
- A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo as SC Injection CI brief — competitive landscape report
- Placebo as SC Injection updates RSS · CI watch RSS
- Carmot Therapeutics, Inc. portfolio CI